Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension study of ofatumumab in relapsing multiple sclerosis
MOH_2018-12-30_004855Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of ofatumumab in multiple sclerosis (MS), sponsored by Novartis. Started Oct 2018; status: active, not recruiting.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on MOH_2018-12-30_004855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-12-30_004855.